CTC Alternative Strategies’s AbbVie ABBV Stock Holding History

CTC Alternative Strategies’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,620	Closed	-$968K	–	145
2025 Q1	$968K	Buy	+4,620	New	+$898K	1.18%	19
2024 Q3	–	Sell	-14,000	Closed	-$2.4M	–	60
2024 Q2	$2.4M	Buy	+14,000	New	+$2.32M	1.02%	15
2023 Q3	–	Sell	-6,900	Closed	-$930K	–	74
2023 Q2	$930K	Buy	+6,900	New	+$1.01M	1.16%	13
2015 Q3	$348K	Buy	+6,400	New	+$417K	0.82%	23

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

CTC Alternative Strategies's ABBV Position: Q2 2025 in Review

CTC Alternative Strategies sold out of AbbVie (ABBV) in Q2 2025, closing a stake of 4,620 shares — an estimated $968K sold.

CTC Alternative Strategies first reported a position in ABBV in Q3 2015 and held it in 4 quarters. The position peaked at $2.4M in Q2 2024. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

CTC Alternative Strategies reported no remaining AbbVie position as of Q2 2025 after selling out during the quarter.
CTC Alternative Strategies sold 4,620 AbbVie shares in Q2 2025, an estimated $968K.
CTC Alternative Strategies first reported a position in AbbVie in Q3 2015 and held it in 4 quarters.
CTC Alternative Strategies's AbbVie position peaked at $2.4M in Q2 2024.
3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on CTC Alternative Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.